Trial Profile
Phase II study of Eribulin in combination with Gemcitabine for the First-line Treatment of Patients with Locally Recurrent or Metastatic Triple Negative Breast Cancer. Protocol ERIGE.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Nov 2020
Price :
$35
*
At a glance
- Drugs Eribulin (Primary) ; Gemcitabine
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms ERIGE
- 25 Nov 2020 Status changed from recruiting to completed.
- 06 Jun 2017 Results (n=83), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 12 Dec 2015 Trial design presented at the 38th Annual San Antonio Breast Cancer Symposium